{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:30:06Z","timestamp":1789745406234,"version":"4.0.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-024-01176-7","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T10:02:23Z","timestamp":1730887343000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Neutrophil-to-lymphocyte ratio as a prognostic indicator of mortality in Polycythemia Vera: insights from a prospective cohort analysis"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2747-6327","authenticated-orcid":false,"given":"Tiziano","family":"Barbui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9664-7084","authenticated-orcid":false,"given":"Alessandra","family":"Carobbio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Ghirardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Fenili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Finazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Castelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5755-0730","authenticated-orcid":false,"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1809-284X","authenticated-orcid":false,"given":"Paola","family":"Guglielmelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3739-7502","authenticated-orcid":false,"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9104-6172","authenticated-orcid":false,"given":"Naseema","family":"Gangat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4605-3821","authenticated-orcid":false,"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,6]]},"reference":[{"key":"1176_CR1","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1182\/blood-2011-11-394775","volume":"119","author":"HC Hasselbalch","year":"2012","unstructured":"Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood. 2012;119:3219\u201325.","journal-title":"Blood"},{"key":"1176_CR2","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1002\/ajh.27002","volume":"98","author":"A Tefferi","year":"2023","unstructured":"Tefferi A, Barbui T. Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98:1465\u201387.","journal-title":"Am J Hematol"},{"key":"1176_CR3","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/145293","volume":"2015","author":"S Hermouet","year":"2015","unstructured":"Hermouet S, Bigot-Corbel E, Gardie B. Pathogenesis of myeloproliferative neoplasms: role and mechanisms of chronic inflammation. Mediators Inflamm. 2015;2015:145293.","journal-title":"Mediators Inflamm"},{"key":"1176_CR4","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.3390\/cancers12082038","volume":"12","author":"G Ramanathan","year":"2020","unstructured":"Ramanathan G, Hoover BM, Fleischman AG. Impact of Host, Lifestyle and Environmental Factors in the Pathogenesis of MPN. Cancers (Basel). 2020;12:2038.","journal-title":"Cancers (Basel)"},{"key":"1176_CR5","doi-asserted-by":"publisher","first-page":"5796","DOI":"10.1002\/cam4.1815","volume":"7","author":"KM Pedersen","year":"2018","unstructured":"Pedersen KM, Bak M, S\u00f8rensen AL, Zwisler A-D, Ellervik C, Larsen MK, et al. Smoking is associated with increased risk of myeloproliferative neoplasms: A general population-based cohort study. Cancer Med. 2018;7:5796\u2013802.","journal-title":"Cancer Med"},{"key":"1176_CR6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3324\/haematol.2010.031070","volume":"96","author":"T Barbui","year":"2011","unstructured":"Barbui T, Carobbio A, Finazzi G, Vannucchi AM, Barosi G, Antonioli E, et al. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica. 2011;96:315\u20138.","journal-title":"Haematologica"},{"key":"1176_CR7","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-017-0425-z","volume":"10","author":"F Lussana","year":"2017","unstructured":"Lussana F, Carobbio A, Salmoiraghi S, Guglielmelli P, Vannucchi AM, Bottazzi B, et al. Driver mutations (JAK2V617F, MPLW515L\/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera. J Hematol Oncol. 2017;10:54.","journal-title":"J Hematol Oncol"},{"key":"1176_CR8","doi-asserted-by":"publisher","first-page":"5421","DOI":"10.3390\/ijms22115421","volume":"22","author":"S Hibino","year":"2021","unstructured":"Hibino S, Kawazoe T, Kasahara H, Itoh S, Ishimoto T, Sakata-Yanagimoto M, et al. Inflammation-induced tumorigenesis and metastasis. Int J Mol Sci. 2021;22:5421.","journal-title":"Int J Mol Sci"},{"key":"1176_CR9","doi-asserted-by":"publisher","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","volume":"106","author":"AJ Templeton","year":"2014","unstructured":"Templeton AJ, McNamara MG, \u0160eruga B, Vera-Badillo FE, Aneja P, Oca\u00f1a A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106:dju124.","journal-title":"J Natl Cancer Inst"},{"key":"1176_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00625-5","volume":"12","author":"A Carobbio","year":"2022","unstructured":"Carobbio A, Vannucchi AM, De Stefano V, Masciulli A, Guglielmelli P, Loscocco GG, et al. Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera. Blood Cancer J. 2022;12:28.","journal-title":"Blood Cancer J"},{"key":"1176_CR11","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nri3024","volume":"11","author":"A Mantovani","year":"2011","unstructured":"Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol. 2011;11:519\u201331.","journal-title":"Nat Rev Immunol"},{"key":"1176_CR12","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00281-013-0374-8","volume":"35","author":"S Jaillon","year":"2013","unstructured":"Jaillon S, Galdiero MR, Del Prete D, Cassatella MA, Garlanda C, Mantovani A. Neutrophils in innate and adaptive immunity. Semin Immunopathol. 2013;35:377\u201394.","journal-title":"Semin Immunopathol"},{"key":"1176_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00994-z","volume":"14","author":"MK Larsen","year":"2024","unstructured":"Larsen MK, Skov V, Kj\u00e6r L, Eickhardt-Dalb\u00f8ge CS, Knudsen TA, Kristiansen MH, et al. Neutrophil-to-lymphocyte ratio and all-cause mortality with and without myeloproliferative neoplasms-a Danish longitudinal study. Blood Cancer J. 2024;14:28.","journal-title":"Blood Cancer J"},{"key":"1176_CR14","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","volume":"23","author":"R Marchioli","year":"2005","unstructured":"Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23:2224\u201332.","journal-title":"J Clin Oncol"},{"key":"1176_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1208500","volume":"368","author":"R Marchioli","year":"2013","unstructured":"Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N. Engl J Med. 2013;368:22\u201333.","journal-title":"N. Engl J Med"},{"key":"1176_CR16","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/leu.2013.163","volume":"27","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27:1874\u201381.","journal-title":"Leukemia"},{"key":"1176_CR17","doi-asserted-by":"crossref","unstructured":"Barbui T, Carobbio A, Guglielmelli P, Ghirardi A, Fenili F, Loscocco GG, et al. Neutrophil\/lymphocyte ratio identifies low-risk polycythemia vera patients for early ropeginterferon Alpha-2b Therapy. Br J Haematol. 2024.","DOI":"10.1111\/bjh.19813"},{"key":"1176_CR18","doi-asserted-by":"publisher","first-page":"E25","DOI":"10.1503\/cmaj.191024","volume":"192","author":"M Warny","year":"2020","unstructured":"Warny M, Helby J, Nordestgaard BG, Birgens H, Bojesen SE. Incidental lymphopenia and mortality: a prospective cohort study. CMAJ. 2020;192:E25\u2013E33.","journal-title":"CMAJ"},{"key":"1176_CR19","unstructured":"Tefferi A, Loscocco GG, Iftikhar M, Rana MS, Jadoon Y, Atanasio, A, et al. Revised International Working Group Risk Model for Survival in Polycythemia Vera. Submitted to the ASH Congress (2024)."},{"key":"1176_CR20","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1056\/NEJMoa035572","volume":"350","author":"R Landolfi","year":"2004","unstructured":"Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N. Engl J Med. 2004;350:114\u201324.","journal-title":"N. Engl J Med"},{"key":"1176_CR21","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1200\/JCO.22.01935","volume":"41","author":"CN Harrison","year":"2023","unstructured":"Harrison CN, Nangalia J, Boucher R, Jackson A, Yap C, O\u2019Sullivan J, et al. Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial. J Clin Oncol. 2023;41:3534\u201344.","journal-title":"J Clin Oncol"},{"key":"1176_CR22","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1056\/NEJMoa2308809","volume":"390","author":"M Kremyanskaya","year":"2024","unstructured":"Kremyanskaya M, Kuykendall AT, Pemmaraju N, Ritchie EK, Gotlib J, Gerds A, et al. Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera. N. Engl J Med. 2024;390:723\u201335.","journal-title":"N. Engl J Med"},{"key":"1176_CR23","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","volume":"7","author":"H Gisslinger","year":"2020","unstructured":"Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7:e196\u2013e208.","journal-title":"Lancet Haematol"},{"key":"1176_CR24","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1182\/blood.2023021503","volume":"142","author":"JP Bewersdorf","year":"2023","unstructured":"Bewersdorf JP, How J, Masarova L, Bose P, Pemmaraju N, Mascarenhas J, et al. Moving toward disease modification in polycythemia vera. Blood. 2023;142:1859\u201370.","journal-title":"Blood"},{"key":"1176_CR25","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1080\/10428194.2022.2070914","volume":"64","author":"K Abu-Zeinah","year":"2023","unstructured":"Abu-Zeinah K, Saadeh K, Silver RT, Scandura JM, Abu-Zeinah G. Excess mortality in younger patients with myeloproliferative neoplasms. Leuk Lymphoma. 2023;64:725\u20139.","journal-title":"Leuk Lymphoma"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01176-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01176-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01176-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T10:05:25Z","timestamp":1730887525000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01176-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,6]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1176"],"URL":"https:\/\/doi.org\/10.1038\/s41408-024-01176-7","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,6]]},"assertion":[{"value":"5 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Results of this trials were derived from ECLAP randomized clinical trial (NEJM 350;2, 2004). In this study the following information was provided \u201cThe study protocol conformed to good clinical practice for trials and to the 2000 revision of the Declaration of Helsinki regarding medical research in humans. We obtained the approval of each local ethics committee before the start of the trial. All patients provided written informed consent. The study was conceived, conducted, and analyzed by the independent investigators under the aegis of the steering committee\u201d.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"195"}}